In Phase C, members will get ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Members will obtain treatment until illness progression or even the participants are unable to tolerate the study drugs. For all stream cytometry experiments, ten,000 cells for every replicate had been analyzed, https://epictetusx111jue3.livebloggs.com/profile